Skip to main content
logo
GE HealthCare Technologies Inc. (GEHC)
NASDAQ: GEHC · Real-Time Price · USD
61.51
+0.75 (1.23%)
At close: May 18, 2026, 4:00 PM EDT
61.70
+0.19 (0.31%)
After-hours: May 18, 2026, 7:59 PM EDT

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Product Revenue
13.89B13.66B13.08B
Product Revenue Growth
1.67%4.48%-0.40%
Service Revenue
7.09B6.96B6.60B
Service Revenue Growth
1.81%5.56%2.68%
Revenue (Total)
20.98B20.63B19.67B
Revenue (Total) Growth
1.72%4.84%0.61%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Imaging Revenue (Post-Q2 2024)
9.40B9.25B8.86B
Imaging Revenue (Post-Q2 2024) Growth
1.72%4.40%-1.00%
Advanced Visualization Solutions (AVS) Revenue
5.46B5.35B5.13B
Advanced Visualization Solutions (AVS) Revenue Growth
1.91%4.35%0.73%
Patient Care Solutions (PCS) Revenue
3.04B3.09B3.13B
Patient Care Solutions (PCS) Revenue Growth
-1.55%-1.25%-0.54%
Pharmaceutical Diagnostics (PDx) Revenue
3.04B2.90B2.51B
Pharmaceutical Diagnostics (PDx) Revenue Growth
4.76%15.63%8.76%
Other Revenue
46.00M40.00M52.00M
Other Revenue Growth
15.00%-23.08%-21.21%
Revenue (Total)
20.98B20.63B19.67B
Revenue (Total) Growth
1.72%4.84%0.61%

Revenue Breakdown 3

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Patient Care Solutions (PCS) Revenue
3.04B3.09B3.13B
Patient Care Solutions (PCS) Revenue Growth
-1.55%-1.25%-0.54%
Pharmaceutical Diagnostics (PDx) Revenue
3.04B2.90B2.51B
Pharmaceutical Diagnostics (PDx) Revenue Growth
4.76%15.63%8.76%
Other Revenue
46.00M40.00M52.00M
Other Revenue Growth
15.00%-23.08%-21.21%
Revenue (Total)
20.98B20.63B19.67B
Revenue (Total) Growth
1.72%4.84%0.61%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
USCAN Revenue
9.66B9.53B8.98B
USCAN Revenue Growth
1.30%6.12%5.03%
EMEA Revenue
5.59B5.43B5.05B
EMEA Revenue Growth
3.06%7.40%-0.14%
China Revenue
2.23B2.25B2.36B
China Revenue Growth
-1.16%-4.62%-15.26%
Rest of World Revenue
3.51B3.42B3.28B
Rest of World Revenue Growth
2.63%4.21%3.86%
Revenue (Total)
20.98B20.63B19.67B
Revenue (Total) Growth
1.72%4.84%0.61%

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Imaging EBIT (Post-Q2 2024)
872.00M891.00M962.00M
Imaging EBIT (Post-Q2 2024) Growth
-2.13%-7.38%17.17%
Advanced Visualization Solutions (AVS) EBIT
1.21B1.18B1.12B
Advanced Visualization Solutions (AVS) EBIT Growth
3.23%5.10%-0.53%
Patient Care Solutions (PCS) Segment EBIT
171.00M209.00M347.00M
Patient Care Solutions (PCS) Segment EBIT Growth
-18.18%-39.77%-9.40%
Pharmaceutical Diagnostics (PDx) Segment EBIT
864.00M872.00M783.00M
Pharmaceutical Diagnostics (PDx) Segment EBIT Growth
-0.92%11.37%26.90%
Other Segment EBIT
10.00M7.00M2.00M
Other Segment EBIT Growth
42.86%250.00%-81.82%
Operating Income (Other)
-481.00M-391.00M-587.00M
Operating Income (Total)
2.65B2.76B2.63B
Operating Income (Total) Growth
-4.13%5.26%7.80%

EBIT 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Patient Care Solutions (PCS) Segment EBIT
171.00M209.00M347.00M
Patient Care Solutions (PCS) Segment EBIT Growth
-18.18%-39.77%-9.40%
Pharmaceutical Diagnostics (PDx) Segment EBIT
864.00M872.00M783.00M
Pharmaceutical Diagnostics (PDx) Segment EBIT Growth
-0.92%11.37%26.90%
Other Segment EBIT
10.00M7.00M2.00M
Other Segment EBIT Growth
42.86%250.00%-81.82%
Operating Income (Total)
2.65B2.76B2.63B
Operating Income (Total) Growth
-4.13%5.26%7.80%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Products Remaining Performance Obligations (RPO)
5.14B5.00B4.76B
Products Remaining Performance Obligations (RPO) Growth
2.78%5.17%-3.55%
Services Remaining Performance Obligations (RPO)
10.69B10.73B9.74B
Services Remaining Performance Obligations (RPO) Growth
-0.37%10.18%0.12%
Total Remaining Performance Obligations (RPO)
15.83B15.73B14.49B
Total Remaining Performance Obligations (RPO) Growth
0.63%8.54%-1.12%
Updated Apr 29, 2026. Data Source: Fiscal.ai.